Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2000
05/18/2000WO2000008202A3 3-methylidenyl-2-indolinone modulators of protein kinase
05/18/2000WO2000008193A3 Latency-active regulatory sequences of herpesviruses and latency-inactive herpesvirus for gene transfer
05/18/2000WO2000008141A3 Short oligonucleotides for the inhibition of vegf expression
05/18/2000WO2000008140A3 Antisense oligonucleotides for the inhibition of vegf expression
05/18/2000WO2000007979A3 Compounds and compositions for delivering active agents
05/18/2000WO2000007580A3 Pharmaceutical compositions against autoimmune diseases
05/18/2000WO2000007544A3 Vitronectin receptor antagonists
05/18/2000WO2000006140A3 Use of moclobemide for treating certain phsychiatric and medical disorders
05/18/2000WO2000004892A3 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
05/18/2000WO2000003740A3 Use of (s) (-)-amisulpride for the manufacture of a medicament for the treatment of schizophrenia
05/18/2000WO2000000514A3 Synthetic spiroketal pyranes as potent anti-cancer agents
05/18/2000WO2000000207A9 Treatment of hyperproliferative disorders
05/18/2000WO2000000186A9 Method of treating topical ailments
05/18/2000WO1999058096A3 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
05/18/2000WO1999045911A8 Universal reed-solomon coder-decoder
05/18/2000DE19852245A1 5-Aminolävulinsäure-Nanoemulsion 5-aminolevulinic acid nanoemulsions
05/18/2000DE19850718C1 Zellpermeabilität-vermittelndes Polypeptid Cell permeability-mediating polypeptide
05/18/2000DE19848260A1 Fumarsäure-Mikrotabletten Fumaric microtablets
05/18/2000DE19830770C1 Wasserlösliche Zinkpyruvate bzw. deren Hydrate, Verfahren zu ihrer Herstellung und deren Verwendung Water-soluble zinc pyruvate or hydrates thereof, processes for their preparation and their use
05/18/2000CA2351222A1 Vancoresmycin, a process for its production and its use as a pharmaceutical
05/18/2000CA2351063A1 A system for administering a bioactive agent by inhalation comprising a lipid mixture comprising phosphatidylcholine
05/18/2000CA2351057A1 Combination of a gaba-a alpha 5 inverse agonist and cox-2 inhibitor, nsaid, estrogen or vitamin e
05/18/2000CA2350714A1 Spiro-indolines as y5 receptor antagonists
05/18/2000CA2350667A1 Cross-linked hyaluronic acids and medical uses thereof
05/18/2000CA2350642A1 Crf receptor antagonists and methods relating thereto
05/18/2000CA2350628A1 Hemostatic polymer useful for rapid blood coagulation and hemostasis
05/18/2000CA2350429A1 Neurotrophic diamide and carbamate agents
05/18/2000CA2350316A1 Methods and compositions to lower plasma cholesterol levels
05/18/2000CA2350304A1 Dispersible compositions containing l-dopa ethyl ester
05/18/2000CA2350235A1 Tricyclic pyrazole derivatives
05/18/2000CA2350213A1 Glucose and lipid lowering compounds
05/18/2000CA2350211A1 Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts
05/18/2000CA2350208A1 Antrhranilic acid amides and the use thereof as medicaments
05/18/2000CA2350182A1 Connective tissue growth factor (ctgf) and methods of use
05/18/2000CA2350133A1 A method for treating tissue damaged from ischemia
05/18/2000CA2350087A1 Chromosome 17p-linked prostate cancer susceptibility gene
05/18/2000CA2350086A1 Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
05/18/2000CA2350071A1 Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis
05/18/2000CA2350062A1 Combinations comprising a beta-agonist and a further antidiabetic agent
05/18/2000CA2350058A1 Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody
05/18/2000CA2349951A1 Platelet-derived growth factor d, dna coding therefor, and uses thereof
05/18/2000CA2349947A1 Method of producing vitamin powders
05/18/2000CA2349904A1 Crf receptor antagonists and methods relating thereto
05/18/2000CA2349761A1 Corticosteroid synthesis-associated genes
05/18/2000CA2349720A1 Stimulation of angiogenesis via syndecan-4 cytoplasmic domain signaling pathway
05/18/2000CA2349700A1 Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
05/18/2000CA2349679A1 Modified exosomes and uses
05/18/2000CA2349592A1 Use of gm-csf to inhibit development of drug resistance in hiv+ patients
05/18/2000CA2349498A1 Methods and compositions for treating or preventing peripheral neuropathies
05/18/2000CA2349445A1 Antisense oligomer
05/18/2000CA2349245A1 New esters derived from substituted phenyl-cyclohexyl compounds
05/18/2000CA2348946A1 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases
05/18/2000CA2348900A1 Disposable premoistened wipe containing an antimicrobial protease inhibitor
05/18/2000CA2348885A1 Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
05/18/2000CA2348763A1 Novel compounds and medicinal use thereof
05/18/2000CA2347916A1 Inhibition of the formation of vascular hyperpermeability
05/18/2000CA2346898A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as vegf receptor tyrosine kinase inhibitors
05/18/2000CA2346108A1 Gastrin and cholecystokinin receptor ligands
05/18/2000CA2345459A1 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof
05/18/2000CA2318162A1 Oxy-vanadium (iv) complexes having spermicidal activity
05/18/2000CA2317049A1 Topical compositions containing whey proteins
05/17/2000EP1001034A1 Arachidonic acid and methods for the production and use thereof
05/17/2000EP1001023A2 Frizzled-4, a putative Wnt-receptor
05/17/2000EP1000952A2 New 2-halogenated derivatives of 5-O-deosaminylerythronolide A, process for making them as well as their use as medicines
05/17/2000EP1000945A1 PROCESS FOR PRODUCING $g(b)-LACTAM DERIVATIVES
05/17/2000EP1000941A1 Diaminorhodamine derivatives
05/17/2000EP1000938A1 Heterocyclic compounds as pharmaceuticals
05/17/2000EP1000930A2 Tachykinin antagonists
05/17/2000EP1000927A2 Excitatory amino acid receptor modulators
05/17/2000EP1000624A1 Use of DOP as antioxidant, anti-ageing additive and medicament
05/17/2000EP1000623A1 Use of epinastine as antitussivum
05/17/2000EP1000622A2 Antiviral agents
05/17/2000EP1000621A2 Use of 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz (CD) indoles for treating motion sickness and vomiting
05/17/2000EP1000619A2 Method for treating glaucoma
05/17/2000EP1000618A1 Topical capsaicin preparation
05/17/2000EP1000617A2 Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor
05/17/2000EP1000615A2 Preparation of pharmaceutically active particles
05/17/2000EP1000606A2 Weak acid skin cleanser containing an alkali salt of N-acyl-amino acid
05/17/2000EP1000166A2 Inhibitors of cell-cycle progression and uses related thereto
05/17/2000EP1000158A1 Endogenetic retroviral sequences, associated with autoimmune diseases or with pregnancy disorders
05/17/2000EP1000145A1 Heart and skeleton muscle specific nucleic acid, the production and use thereof
05/17/2000EP1000144A2 Lactoferrin receptor genes of moraxella
05/17/2000EP1000084A1 123 human secreted proteins
05/17/2000EP1000082A2 Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
05/17/2000EP1000080A1 Lyxofuranosyl benzimidazoles as antiviral agents
05/17/2000EP1000079A1 New formulation
05/17/2000EP1000078A1 HYBRID ANTHRACYCLINES FROM GENETICALLY ENGINEERED $i(STREPTOMYCES GALILAEUS) STRAINS
05/17/2000EP1000077A1 Synthetic insulin mimetic substances
05/17/2000EP1000075A1 Method of producing tiazofurin and other c-nucleosides
05/17/2000EP1000071A1 Neurologically-active compounds
05/17/2000EP1000067A1 Thiazolobenzoheterocycles, preparation and medicines containing same
05/17/2000EP1000066A1 Fused 1,2,4-thiadiazine derivatives, their preparation and use
05/17/2000EP1000065A1 Preparation of oxymorphone, oxycodone and derivatives
05/17/2000EP1000064A1 Compounds
05/17/2000EP1000063A1 4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO 4,5-$i(b)]-INDOLE-1-ACETAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY
05/17/2000EP1000062A1 Tricyclic vasopressin agonists
05/17/2000EP1000061A1 Therapeutically active 1,2,4-triazolo(4,3-b) pyridazine derivatives as ligands for gaba receptors
05/17/2000EP1000060A1 Novel compounds
05/17/2000EP1000059A1 Tricyclic vasopressin agonists
05/17/2000EP1000057A1 Pyridyl- and pyrimidyl-heterocyclic compounds inhibiting oxido squalene-cyclase
1 ... 6316 6317 6318 6319 6320 6321 6322 6323 6324 6325 6326 6327 6328 6329 6330 6331 6332 6333 6334 6335 6336 ... 7860